TÜRKİYE’DE NÖROLOJİK HASTALIKLARA ATFEDİLEN ENGELLİLİĞE GÖRE AYARLANMIŞ YAŞAM YILLARININ (DALY’LERİN) EKONOMİK YÜKÜNÜN BELİRLENMESİ

Abstract

Bu çalışma, Türkiye’de 1990–2023 döneminde nörolojik hastalıklara bağlı Engelliliğe Göre Ayarlanmış Yaşam Yılları (Disability-Adjusted Life Years; DALY) kayıplarının ekonomik değerinin tahmin edilmesi amaçlamaktadır. Analiz, hastalık yükü metodolojisi ve beşerî sermaye yaklaşımı çerçevesinde yürütülmüş; DALY değerleri kişi başına ekonomik katkı ile çarpılarak üretkenlik kaybına dayalı parasal karşılıklara dönüştürülmüştür. Bulgular, nörolojik hastalıklara atfedilen toplam ekonomik yükün 1990 yılında yaklaşık 172 milyon dolardan 2023 yılında 221 milyon dolara yükseldiğini göstermektedir. Bu ekonomik kaybın Gayri Safi Yurt İçi Hasıla (GSYİH) içindeki payı 1990’ların başında %1,0–1,3 aralığında seyrederken, GSYİH’nin hastalık yüküne kıyasla daha hızlı büyümesi nedeniyle 2000’li yılların ortasında yaklaşık %0,3 düzeyine gerilemiştir. Baş ağrısı bozuklukları ve Alzheimer hastalığı analiz edilen dönem boyunca en yüksek ekonomik yükü oluşturan hastalık gruplarıdır. Ekonomik kaybın büyük bölümünün Engellilikle Yaşanan Yıllar (Years Lived with Disability; YLD) bileşeninden kaynaklanması, nörolojik hastalıkların ekonomik etkisinin esas olarak uzun süreli engellilikten doğduğunu ve engelliliği azaltmaya yönelik maliyet-etkili müdahalelerin önceliklendirilmesi gerektiğini göstermektedir.

Keywords

• Anahtar Kelimeler: Nörolojik Hastalıklar
• Hastalık Yükü
• Engelliliğe Göre Ayarlanmış Yaşam Yılları (DALY)
• İnsan Sermayesi Yaklaşımı

Supporting Institution

Çalışmada herhangi bir kurum ya da kuruluştan destek alınmamıştır.

Ethical Statement

Bu çalışma, kamuya açık ve anonimleştirilmiş ikincil veri kaynaklarından (IHME/GBD, TÜİK, OECD, Dünya Bankası vb.) elde edilen veriler kullanılarak yürütülmüştür. Araştırmada herhangi bir insan veya hayvan deneğiyle doğrudan temas, klinik uygulama veya müdahale söz konusu olmadığından etik kurul onayı gerektirmemektedir.

THE ECONOMIC BURDEN OF DISABILITY-ADJUSTED LIFE YEARS (DALYs) ATTRIBUTABLE TO NEUROLOGICAL DISORDERS IN TÜRKİYE

Abstract

This study estimates the economic value of Disability-Adjusted Life Years (DALYs) attributable to neurological disorders in Türkiye between 1990 and 2023. The analysis was conducted within the burden of disease framework and the human capital approach; DALY estimates were multiplied by per capita economic output to convert productivity losses into monetary values. Findings show that the total economic burden increased from approximately USD 172 million in 1990 to USD 221 million in 2023. Although this loss accounted for 1.0–1.3% of Gross Domestic Product (GDP) in the early 1990s, its share declined to around 0.3% by the mid-2000s as GDP grew faster than disease burden. Headache disorders and Alzheimer’s disease were the leading contributors throughout the study period. The predominance of Years Lived with Disability (YLD) indicates that the economic impact is mainly driven by long-term disability, highlighting the need for cost-effective disability-reducing interventions.

Keywords

• Neurological Disorders
• Burden of Disease
• Disability-Adjusted Life Years (DALY)
• Human Capital Approach

Supporting Institution

The research was not supported by any institution.

Ethical Statement

This study assesses the economic value of Disability-Adjusted Life Years (DALYs) attributable to neurological disorders in Türkiye between 1990 and 2023. Using the burden of disease framework and the human capital approach, DALYs were monetized by multiplying them by per capita economic contribution to estimate productivity losses. The findings show that the total economic burden of neurological diseases increased from approximately USD 172 million in 1990 to USD 221 million in 2023. While the absolute burden rose, its share of gross domestic product (GDP) declined from about 1.0–1.3% in the early 1990s to nearly 0.3% in the mid-2000s. Headache disorders and Alzheimer’s disease were the leading contributors to the overall economic burden throughout the study period. The dominance of the Years Lived with Disability (YLD) component indicates that long-term disability, rather than premature mortality, constitutes the primary driver of economic losses associated with neurological diseases, emphasizing the need for cost-effective disability-reducing interventions in health policy.

References

1. Barro, R. J. (1991). Economic growth in a cross section of countries. Quarterly Journal of Economics, 106(2), 407–443.
2. Becker, G. S. (1964). Human capital: A theoretical and empirical analysis, with special reference to education. University of Chicago Press.
3. Brown, D. W. (2008). Economic value of disability-adjusted life years lost to violence: Estimates for WHO Member States. Revista Panamericana de Salud Pública, 24(3), 203–209. https://doi.org/10.1590/S1020-49892008000900007
4. Dalal, K., & Svanström, L. (2015). Economic burden of disability adjusted life years (DALYs) of injuries in a low-income country. Journal of Safety Research, 52, 25–30.
5. European Brain Council. (2025). Annual Report 2024. Brussels: European Brain Council. Retrieved from https://www.braincouncil.eu/reports/annual-report-2024
6. GBD 2015 Neurological Disorders Collaborator Group. (2017). Global, regional, and national burden of neurological disorders during 1990–2015: A systematic analysis for the Global Burden of Disease Study 2015. The Lancet Neurology, 16(11), 877–897. https://doi.org/10.1016/S1474-4422(17)30299-5
7. GBD 2016 Neurology Collaborators. (2019). Global, regional, and national burden of neurological disorders, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 18(5), 459–480. https://doi.org/10.1016/S1474-4422(18)30499-X
8. GBD 2016 Parkinson’s Disease Collaborators. (2018). Global, regional, and national burden of Parkinson’s disease, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet Neurology, 17(11), 939–953. https://doi.org/10.1016/S1474-4422(18)30295-3

9. GBD 2019 Diseases and Injuries Collaborators. (2020). Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019. The Lancet, 396(10258), 1204–1222.
10. GBD 2021 Nervous System Disorders Collaborators. (2024). Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2021. The Lancet Neurology, 23(4), 344–381. https://doi.org/10.1016/S1474-4422(23)00412-1
11. Institute for Health Metrics and Evaluation (IHME). (2024). Global Burden of Disease Study 2023 (GBD 2023) results. Seattle, WA: IHME. Retrieved from https://vizhub.healthdata.org/gbd-results
12. Kirigia, J. M., & Kubai, P. K. (2023). Monetary value of disability-adjusted life years and potential productivity losses associated with neglected tropical diseases in the East African Community. Research and Reports in Tropical Medicine, 14, 35–47. https://doi.org/10.2147/RRTM.S382288
13. Kirigia, J. M., & Mburugu, G. N. (2017). The monetary value of human lives lost due to neglected tropical diseases in Africa. Infectious Diseases of Poverty, 6(1), 1–16. https://doi.org/10.1186/s40249-017-0379-y
14. Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. L. (2006). Global burden of disease and risk factors. World Bank & Oxford University Press.
15. Lucas, R. E. (1988). On the mechanics of economic development. Journal of Monetary Economics, 22(1), 3–42.
16. Mathers, C. D., Fat, D. M., & Boerma, J. T. (2007). The global burden of disease: 2004 update. World Health Organization.
17. Mooney, G., & Wiseman, V. (2000). Burden of disease and priority setting. Health Policy and Planning, 15(4), 369–379.
18. Murray, C. J. L., & Lopez, A. D. (1996). The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Harvard School of Public Health.
19. Murray, C. J. L. (2022). The Global Burden of Disease Study at 30 years. Nature Medicine, 28(10), 2019–2026. https://doi.org/10.1038/s41591-022-01990-1
20. Muthuri, R. N. D. K., & Kirigia, J. M. (2020). The monetary value of disability-adjusted life years in Kenya in 2017. SAGE Open, 10(4), 2158244020970556. https://doi.org/10.1177/2158244020970556
21. Organisation for Economic Co-operation and Development (OECD). (2024). OECD Health Statistics. Paris: OECD. https://www.oecd.org/health/health-data.htm
22. Park, M. J., Han, S. H., & Kim, K. S. (2019). Health policy and burden of disease approach for national health planning. Korean Journal of Health Policy and Administration, 29(1), 1–9.
23. Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer Report 2015: The global impact of dementia. Alzheimer’s Disease International.
24. R Core Team. (2025). R: A language and environment for statistical computing [Computer software]. R Foundation for Statistical Computing. https://www.R-project.org/
25. Rice, D. P. (2000). Cost of illness studies: What is good about them? Injury Prevention, 6(3), 177–179.
26. Roche. (2023). Understanding the global impact of neurological conditions. Roche. Retrieved October 28, 2025, from https://www.roche.com/stories/understanding-global-impact-neurological-conditions
27. Romer, P. M. (1990). Endogenous technological change. Journal of Political Economy, 98(5), S71–S102. Sağlık Bakanlığı. (2019). Türkiye sağlık profili 2019 raporu. T.C. Sağlık Bakanlığı.
28. Schultz, T. W. (1971). Investment in human capital: The role of education and of research. Free Press. Statistical Commission & UN Economic Commission for Europe. (2004). Measuring health status: Conceptual framework and guidelines. United Nations.
29. Türkiye İstatistik Kurumu (TÜİK). (2024). Ulusal hesaplar ve sağlık istatistikleri. Ankara: TÜİK. https://data.tuik.gov.tr
30. Weisbrod, B. A. (1961). Economics of public health: Measuring the economic impact of diseases. Philadelphia, PA: University of Pennsylvania Press.
31. Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., Prina, M., & Prince, M. (2018). The worldwide costs of dementia 2015 and comparisons with 2010. Alzheimer’s & Dementia, 14(1), 1–7.
32. World Bank. (1993). World development report 1993: Investing in health. Oxford University Press.
33. World Bank. (2024). World Development Indicators. Washington, DC: World Bank. https://databank.worldbank.org/source/world-development-indicators
34. World Health Organization (WHO). (2006). Neurological disorders: Public health challenges. World Health Organization.
35. World Health Organization. (2019). International statistical classification of diseases and related health problems (10th rev.).
36. World Health Organization (WHO). (2020). World health statistics 2020: Monitoring health for the SDGs. World Health Organization.
37. World Health Organization Europe. (2021). European health report 2021. WHO Regional Office for Europe.
38. World Health Organization (WHO). (2022). World health statistics 2022: Monitoring health for the SDGs, sustainable development goals. Geneva: World Health Organization. https://www.who.int/data/gho/publications/world-health-statistics
39. World Health Organization (WHO). (2023). World health statistics 2023: Monitoring health for the SDGs. World Health Organization.
40. Yiğit, A. (2020). Hastalık yükü: Kavramsal bir çerçeve. In E. Eke (Ed.), Sağlık yönetiminde güncel tartışmalar (s. 185–199). Nobel Kitabevi.
41. Yiğit, A. (2022). Economic burden of disability-adjusted life years (DALYs) of cancer in Turkey. International Journal of Health Management and Tourism, 7(3), 377–388. https://doi.org/10.31201/ijhmt.1197407